EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

THE EFFECTIVENESS OF METFORMIN THERAPY IN PREVENTING THE PROGRESSION OF PREDIABETES TO TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES

Muhammad Sufi Sidabutar

The International Journal of Medical Science and Health Research · 19.11.2026 · 49 (3) · 634-711

DOI: 10.70070/52z1gz72 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The International Journal of Medical Science and Health Research, online erschienen am 19.11.2026. Verfasst von Muhammad Sufi Sidabutar. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Prediabetes, defined by impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or intermediate glycated haemoglobin (HbA1c), affects several hundred million adults and carries an annual risk of progression to type 2 diabetes mellitus (T2DM) of approximately 5–10%. Metformin is the only glucose-lowering agent endorsed for diabetes prevention in selected high-risk individuals, yet its effectiveness outside the Diabetes Prevention Program (DPP), its durability, its effects on glycaemic and metabolic intermediates, and its tolerability in contemporary and low- and middle-income settings have not been synthesised in a single, up-to-date analysis restricted to the past 15 years of publication. We aimed to quantify the effectiveness and safety of metformin in preventing progression from prediabetes to T2DM.

Methods

This review followed the PRISMA 2020 statement. PubMed, Europe PMC, Semantic Scholar and ClinicalTrials.gov were searched for reports published from January 2011 to 12 November 2026, supplemented by citation searching. Randomised controlled trials (RCTs), comparative studies, cohorts and case series of adults with prediabetes receiving metformin (alone, added to lifestyle intervention or within a stepped-care strategy) versus placebo, standard care or the same lifestyle intervention were eligible; systematic reviews were excluded from the characteristics tables but used in the Discussion. The primary outcome was incident T2DM. Risk of bias was assessed with RoB 2 and ROBINS-I. Risk ratios (RR), hazard ratios (HR) and mean differences (MD) were pooled with DerSimonian–Laird random-effects models, with Hartung–Knapp–Sidik–Jonkman (HKSJ) adjustment and 95% prediction intervals; certainty was graded with GRADE.

Results

Of 4,826 records, 22 studies (17 RCTs and 5 non-randomised studies; 32 reports; approximately 13,660 participants) were included and 13 contributed to quantitative synthesis. Metformin reduced incident T2DM (7 RCTs, 5,243 participants; RR 0.84 (95% CI 0.78–0.90); I² = 7%; HKSJ 95% CI 0.77–0.92). The effect was 0.88 (95% CI 0.81–0.94) for metformin-specific comparisons (5 RCTs; I² = 0%) and 0.74 (95% CI 0.63–0.85) for stepped-care strategies incorporating metformin (2 RCTs; P for subgroup difference = 0.04), corresponding to approximately 54 fewer cases per 1,000 treated (number needed to treat ≈ 18). Time-to-event analysis yielded HR 0.79 (95% CI 0.71–0.87) (4 RCTs). Metformin increased reversion to normoglycaemia (3 RCTs; RR 1.27 (95% CI 1.09–1.48)), lowered HbA1c (6 RCTs; MD −0.09%, 95% CI −0.17 to −0.02) and body weight (5 RCTs; MD −1.87 kg, 95% CI −2.68 to −1.06), but did not significantly change fasting plasma glucose (MD −0.14 mmol/L; I² = 71%), 2-hour glucose, homeostasis model assessment of insulin resistance, blood pressure or lipids. Non-adherence or discontinuation was more frequent with metformin (RR 1.74 (95% CI 1.27–2.39)), whereas serious adverse events were not increased; long-term use was associated with biochemical vitamin B12 deficiency. In the DPP, the HR remained 0.82 at 15 years and 0.83 at 21 years, and meta-regression suggested attenuation with longer follow-up (P = 0.05).

Discussion

Metformin produces a modest, consistent and durable reduction in progression to T2DM, with the largest absolute benefit in individuals at the highest baseline risk and when embedded in stepped lifestyle-first programmes. Its glycaemic and weight effects are small, its benefit attenuates over time and after discontinuation, and gastrointestinal intolerance and vitamin B12 deficiency require monitoring. Long-term effects on mortality and microvascular disease have not been demonstrated.

Conclusion

Metformin is an effective, inexpensive and safe adjunct for preventing or delaying T2DM in people with prediabetes (moderate-certainty evidence), particularly when targeted to high-risk phenotypes and integrated into structured lifestyle programmes. Adequately powered trials in Asian, African and Latin American populations, with harmonised glycaemic definitions and patient-important outcomes, are required.

Zitieren

APA

Sidabutar, M. S. (2026). THE EFFECTIVENESS OF METFORMIN THERAPY IN PREVENTING THE PROGRESSION OF PREDIABETES TO TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES. The International Journal of Medical Science and Health Research, 49(3), 634-711. https://doi.org/10.70070/52z1gz72

Vancouver

Sidabutar MS. THE EFFECTIVENESS OF METFORMIN THERAPY IN PREVENTING THE PROGRESSION OF PREDIABETES TO TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES. The International Journal of Medical Science and Health Research. 2026;49(3):634-711. doi:10.70070/52z1gz72

BibTeX
@article{Sidabutar2026,
  author = {Sidabutar, Muhammad Sufi},
  title = {THE EFFECTIVENESS OF METFORMIN THERAPY IN PREVENTING THE PROGRESSION OF PREDIABETES TO TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES},
  journal = {The International Journal of Medical Science and Health Research},
  year = {2026},
  volume = {49},
  number = {3},
  pages = {634--711},
  doi = {10.70070/52z1gz72}
}
Kostenlos starten →